# A Rare, Potentially Fatal Complication of a Common Virus: Epstein-Barr Virus-Induced Hemophagocytic Lymphohistiocytosis in Adolescence

## TL;DR

A 19-year-old woman with Graves' disease developed a rare and severe immune condition triggered by Epstein-Barr virus, highlighting the need for early diagnosis and tailored treatment.

## Contribution

This case emphasizes the link between autoimmune disorders and EBV-induced HLH, suggesting the importance of targeted therapies in such patients.

## Key findings

- A patient with Graves’ disease developed EBV-induced HLH, indicating immune dysregulation may predispose to this condition.
- Identifying the underlying trigger in HLH is crucial for selecting appropriate treatment strategies, including monoclonal antibodies.
- Autoimmune conditions like Graves’ disease may increase susceptibility to severe immune responses following viral infections.

## Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome that requires rapid recognition and treatment. We describe a 19-year-old female patient with a history of Graves’ disease who presented with Epstein-Barr virus (EBV) infection, severe pancytopenia, and was subsequently diagnosed with EBV-induced HLH. The presence of Graves’ disease, an autoimmune thyroid disorder, likely contributed to underlying immune dysregulation, predisposing the patient to an exaggerated immune response when exposed to EBV. This case highlights the importance of maintaining a high index of suspicion for HLH in patients with autoimmune conditions complicated by infection. Equally important is identifying the underlying trigger, as treatment strategies may differ, and include targeted therapies such as monoclonal antibodies in addition to, or in place of, traditional bone marrow-suppressive regimens.